Editor’s Note: The Friday Brief takes a hiatus from regular news to spotlight recent multimedia content.

Happy Friday, happy 250th birthday to the USA, and happy holiday edition of The Friday Brief.

It is now July, which means we are busy putting together our annual Top 20 pharma and biopharma companies issue. We saw many of you interested in last year’s edition when we met last week at BIO in San Diego. We’re confident you’ll dive into the 2026 update.

In fact, there’s a bit of a preview up right now on our Exclusives page. We’ve already revealed the top 10 for fiscal year ’25 based on pharmaceutical sales. Who moved up, who moved down? You can see it right now at contractpharma.com.

The June issue of Contract Pharma is, of course, still available at contractpharma.com. The cover story: scaling cell & gene therapy. But there’s plenty else inside—on the future of biotech outsourcing, QbD in biologics formulation development, and rethinking quality management.

What we really want to highlight, though, is some of the other coverage we’ve brought you online recently. In the absence of news this weekend, we want to keep things fresh by spotlighting content you may have missed.

We’ve had five new additions to our Pharma Matters Q&A series in June. These contributions came from Lifecore Injectables CDMO, Nelson Laboratories, Quotient Sciences, Thermo Fisher Scientific, and Valsynthese.

Even though we just finished with BIO, we rewind back to the beginning of June with a VideoBite from CPHI Americas. In Philly, we spoke to Aaron Dely, VP of R&D at PLD Pharma Services, about reducing risk in product transfers. Worth a watch.

We’ve also dropped a handful of new podcasts. We know it’s a popular format; we’re working to bring you more with companies and topics crucial to your business.

And, don’t forget the new Contract Pharma Stream, our on-demand archive of webinars, providing another multimedia option to dive into.

That should keep you busy until we are back to start the second half of the year on Monday. And, we’ll be right back here next Friday, on The Friday Brief.